|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The deal, first announced in September, resulted from a strategic review initiated last year by Lpath.
Apollo Endosurgery, Inc. , a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it has completed its merger transaction with Lpath, Inc.
Categories: Yahoo Finance Get free summary analysis Lpath, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Lpath, Inc. – PDL BioPharma, Inc., Pfizer Inc., Gilead Sciences, Inc., Acorda Therapeutics, Inc. and Merck & Co., Inc. (PDLI-US, PFE-US, GILD-US, ACOR-US and MRK-US) that have also reported ... Read more (Read more...)